Whether a high-dose influenza vaccine is associated with a benefit in reducing CP events.
Novo Nordisk gears up for FDA filing with late-phase insulin plus semaglutide data
Novo Nordisk, with data on-hand from a late-stage trial of IcoSema, is preparing for an FDA filing in type 2 diabetes slated for the second